CRISPR THERAPEUTICS AG
NASDAQ: CRSP (CRISPR Therapeutics AG)
Kemas kini terakhir: 5 jam lalu40.15
-0.22 (-0.54%)
| Penutupan Terdahulu | 40.37 |
| Jumlah Dagangan | 4,108,033 |
| Harga / Jualan (P/S) | 174.15 |
| Harga / Buku (P/B) | 2.48 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -17,158.84% |
| EPS Cair (TTM) | -4.49 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 71.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.99% |
| Nisbah Semasa (MRQ) | 15.64 |
| Aliran Tunai Operasi (OCF TTM) | -306.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -193.24 M |
| Pulangan Atas Aset (ROA TTM) | -12.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.71% |
Sentimen Berita
- CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
- CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
AISkor Stockmoo
| Nilai 30% | -0.9 |
| Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info | NA |
| Penilaian Relatif info | NA |
| Pertumbuhan Tersirat info | NA |
| Sejarah Penilaian info | NA |
| Hutang rendah. Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info | |
| Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info | |
| Masa 30% | -1.7 |
| Daripada analisis teknikal AI kami terhadap carta. info | NA |
| Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info | |
| Corak Lilin info | NA |
| Aliran bagi Tempoh Pegangan Anda info | NA |
| Sentimen 20% | 0.4 |
| Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info | |
| Berita terkini kebanyakannya positif. info | |
| Wang Pintar 20% | 0.6 |
| Aktiviti Orang Dalam info | NA |
| Institusi bersih +0.42% daripada saham dalam pemfailan 13F terkini: 251 pemegang menambah, 209 mengurang (suku berakhir 30 Sep 2026). info | |
| Kedudukan jual singkat -8.4% dari 31 Aug hingga 30 Oct 2026, 13.1 hari untuk tutup (FINRA). info | |
| Keadaan pasaran dan sektor lemah. | |
| Persekitaran pasaran berhati-hati. info | |
| Sektor ketinggalan berbanding pasaran. | |
| Tonggak-tonggak sependapat, jadi skor diperkukuh. | |
| Tidak dikira dalam skor | |
| Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info | |
| Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info | |
| Paras sokongan dan rintangan menurun. info | |
| Skor Akhir | -0.66 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | CRISPR Therapeutics AG | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| CRSP | - | - | - | 2.48 |
| GMAB | - | - | - | 4.99 |
| REGN | - | 0.39% | - | 2.95 |
| ABVX | - | - | - | 16.72 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 1.69% |
| % Dimiliki oleh Institusi | 76.46% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Ark Investment Management Llc | 30 Sep 2026 | 10,056,844 |
| Orbis Allan Gray Ltd | 30 Sep 2026 | 4,519,261 |
| Gsk Plc | 30 Sep 2026 | 2,608,419 |
| Sumitomo Mitsui Trust Group, Inc. | 30 Sep 2026 | 1,453,713 |
| Amova Asset Management Americas, Inc. | 30 Sep 2026 | 1,453,513 |
Tiada data dalam julat masa ini.
Institusi
Pemilikan institusi: 81.86%
| Kedudukan | Pemegang | Saham |
|---|---|---|
| Bertambah | 251 | 6,196,285 |
| Berkurang | 209 | 6,222,834 |
| Baharu | 65 | 826,959 |
| Dijual habis | 67 | 394,972 |
Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.
Kedudukan Jual Singkat
| Penyelesaian | Saham | Hari untuk tutup |
|---|---|---|
| 30 Oct 2026 | 17,189,067 | 13.1 |
| 15 Oct 2026 | 16,442,415 | 10.2 |
| 30 Sep 2026 | 18,679,198 | 9.6 |
| 15 Sep 2026 | 19,071,093 | 16.5 |
| 31 Aug 2026 | 18,769,995 | 10.7 |
| 14 Aug 2026 | 18,744,855 | 15.6 |
Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store. |
| 17 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
CRISPR Therapeutics (NASDAQ:CRSP) is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY. CEO Sam Kulkarni said during a Jeff… |
| 10 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 10:00 a.m. GMT. A live… |
| 09 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG), who had a median baseline TG level… |
| 08 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response Zugo-cel has been well tolerated in all 21 patients dosed to date, with no… |
| 06 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
| 04 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic… |
| 03 Nov 2026 | Yahoo Finance |
Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead
Vertex stock slumped Tuesday despite notching a definitive beat for its Crispr-partnered blood diseases gene editor, Casgevy. |
| 03 Nov 2026 | Yahoo Finance |
Why Did CRISPR Therapeutics (CRSP) Stock Slide After Its Latest Update?
CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss of US$111.44 million, providing investors with updated financial data to review. The latest quarterly update and pipeline news landed against a backdrop where CRISPR… |
| 03 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for anyone looking at the stock today. Is the current share price meaningfully supported by what sits on its balance sheet in terms of book value, or is the market asking you to pay… |
| 03 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics (CRSP) Appoints Siva Sakhamuri As Chief Technical Officer
CRISPR Therapeutics (NasdaqGM:CRSP) appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer, according to a recent company announcement. Dr. Sakhamuri brings experience leading technical operations and manufacturing functions at established biotechnology enterprises focused on complex… |
| 03 Nov 2026 | Yahoo Finance |
Crispr Therapeutics Reports Growing Casgevy Use Ahead of Key Pipeline Data, RBC Says
Crispr Therapeutics (CRSP) is seeing continued growth in the use of its gene-editing treatment Casge… |
| 03 Nov 2026 | Yahoo Finance |
CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs. |
| 03 Nov 2026 | Yahoo Finance |
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike. |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 02 Nov 2026 | Yahoo Finance |
Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline. |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years… |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
| 02 Nov 2026 | Yahoo Finance |
CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing… |
| 30 Oct 2026 | Yahoo Finance |
Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session. |
| Papar semua | ||
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |